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Abstract
The transcription factor PPARγ is expressed in endothelium and vascular muscle where it may exert
anti-inflammatory and anti-oxidant effects. We tested the hypothesis that PPARγ plays a protective
role in the vasculature by examining vascular structure and function in heterozygous knockin mice
expressing the P465L dominant negative mutation in PPARγ (L/+). In L/+ aorta, responses to the
endothelium-dependent agonist acetylcholine (ACh) were not affected, but there was an increase in
contraction to serotonin, PGF2α, and endothelin-1. In cerebral blood vessels both in vitro and in vivo,
ACh produced dilation that was markedly impaired in L/+ mice. Superoxide levels were elevated in
cerebral arterioles from L/+ mice and responses to ACh were restored to normal with a scavenger of
superoxide. Diameter of maximally dilated cerebral arterioles was less, whereas, wall thickness and
cross-sectional area was greater in L/+ mice, indicating cerebral arterioles underwent hypertrophy
and remodeling. Thus, interference with PPARγ signaling produces endothelial dysfunction via a
mechanism involving oxidative stress and causes vascular hypertrophy and inward remodeling.
These findings indicate that PPARγ has vascular effects which are particularly profound in the
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cerebral circulation and provide genetic evidence that PPARγ plays a critical role in protecting blood
vessels.
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Introduction
The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated
transcription factor which has gained prominence because of its involvement in complex
diseases such as diabetes, obesity, atherosclerosis, and hypertension. Recent interest in the role
of PPARγ in the vasculature has substantially increased because of the anti-inflammatory and
anti-oxidant effects reported for PPARγ agonists [reviewed by 1]. Naturally occurring
mutations in humans, resulting in either constitutive activation or impairment of PPARγ
function, strongly support its physiological importance and illustrate the severe consequences
for cardiovascular related events when PPARγ signaling is altered 2. Individuals with dominant
negative mutations in PPARγ present with early onset hypertension and elements of the
metabolic syndrome 2.
Although the importance of PPARγ in adipose tissue is now well documented, its role in the
cardiovascular system has only begun to emerge. PPARγ is the molecular target of the
thiazolidinediones (TZDs) class of anti-diabetes drugs. These drugs increase insulin sensitivity
but also lower blood pressure in patients with type 2 diabetes 3 and in animal models of
hypertension 4. TZDs also improve endothelial function and reduce blood pressure in non-
diabetic models of hypertension, underscoring the potential protective effects of PPARγ in the
vessel wall 5. PPARγ is expressed in endothelium and vascular muscle and there is growing
evidence that PPARγ may have direct effects in the vasculature 6-10.
We hypothesize that PPARγ plays an important protective role in the regulation of vascular
tone and vascular growth. To address this hypothesis using a genetic approach to avoid potential
non-specific effects of synthetic PPARγ ligands 11, we examined vascular function and
structure using heterozygous knockin mice carrying a dominant negative mutation in PPARγ
(L/+) 12. The P465L mutation is equivalent to the P467L mutation found in humans with insulin
resistance, type II diabetes and hypertension 2.
Methods
Experimental Mice
The inbred colony was maintained by breeding heterozygous P465L mice with 129/SvEv mice
12. The experimental colony (5-9 months of age) was maintained by breeding inbred 129/SvEv
heterozygous P465L knockin mice with C57BL/6J mice, to produce control and heterozygous
P465L mice on an isogenic background. All mice were fed standard chow (LM-485; Teklad
Premier Laboratory Diets) and water ad libitum. Care of the mice used in the experiments met
the standards set forth by the NIH for the care and use of experimental animals. All procedures
were approved by the University Animal Care and Use Committee at the University of Iowa.
Gene Expression Profiling and Computational Analysis
We performed gene expression profiling to gain evidence of dominant negative activity of the
PPARγ P465L mutation as detailed in the Supplemental Methods (see
http://hyper.ahajournals.org). Data from the microarray studies including CEL files have been
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submitted to the Gene Expression Omnibus at NCBI (array platform: GPL1261, series
accession: GSE8949).
Aortic Ring Preparation
Male and female mice were given a lethal dose of pentobarbital (50 to 100 mg/mouse IP), and
the thoracic aorta was quickly removed and prepared for measurements as described in detail
5, 13.
Studies of cerebral arteries in vitro
Male and female mice were given a lethal dose of pentobarbital, the brain removed and the
basilar artery isolated and prepared for measurements of vessel diameter in vitro as described
14. At the end of each experiment papaverine (100 mmol/L) was used to produce maximal
vasodilation. Vasodilator responses are expressed as percent dilation (% of induced tone) with
100% representing the difference between the resting value and the constricted value with
U46619. Agonists used in this study are detailed in the Supplemental Methods (see
http://hyper.ahajournals.org).
Studies of cerebral arterioles in vivo
For studies in vivo, female mice were anesthetized with pentobarbital (75—90 mg/kg ip),
supplemented at ∼20 mg/kg per hour. Mice were ventilated, arterial blood pressure and blood
gases were monitored, and arteriolar diameter was measured using a cranial window 15.
Arterial blood gases were maintained within normal limits (pH=7.35±0.01, PCO2=39±1 mm
Hg, and PO2=119±4 mm Hg). Body temperature was maintained at approximately 37°C with
a heating pad.
Measurements of superoxide and vascular structure
Measurements of superoxide 16 and pressure and diameter in arterioles on the cerebrum was
measured in male and female mice as described previously 17. After obtaining baseline values,
arterioles were suffused with artificial CSF containing EDTA (67 mmol/L) to deactivate
vascular muscle. Pressure-diameter relationships were then obtained in maximally dilated
arterioles using controlled hemorrhage. Maximally dilated arterioles were fixed at
physiological pressure in vivo by suffusion with glutaraldehyde (2.25% in 0.10 mol/L
cacodylate buffer). After the anesthetized animal was killed by injection of KCl, the arteriolar
segment studied was removed, processed, and embedded in Spurr's low viscosity resin while
cross-sectional orientation was maintained. Cross-sectional area of the arteriolar wall was
determined histologically from 1-μm sections.
Statistical Analysis
All data are expressed as mean±SEM. Comparisons were made with 2-way repeated measures
ANOVA using a Tukey post-hoc test or t-test where appropriate. P<0.05 was considered
significant. Data were analyzed by use of SigmaStat (Systat Software).
Results
To gain evidence for dominant negative activity of PPARγ we performed gene expression
profiling of RNA isolated from thoracic aorta comparing those genes regulated by
rosiglitazone, a PPARγ agonist, with those altered by the P465L mutation. Evidence of
dominant negative activity would be obtained if the same genes up-regulated by rosiglitazone
were down-regulated by P465L mutation and vice versa. In aorta, 21 genes up-regulated by
rosiglitazone were down-regulated in P465L, half of them significantly (Table S1,
http://hyper.ahajournals.org). Half of these genes are involved in lipid or carbohydrate
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metabolism, consistent with a role of PPARγ, and nearly all had predicted PPARγ binding sites
in their promoters. Similarly, 75% of 32 genes in aorta which were down-regulated by
rosiglitazone were significantly up-regulated by in P465L mice (Table S2,
http://hyper.ahajournals.org). In contrast, these genes were associated with inflammation, cell
signaling, or oxidoreductase activity. These data provide evidence for dominant negative
activity of the PPARγ P465L mutation in the vasculature.
Aortic rings were pre-contracted with PGF2α and relaxation was measured in response to
increasing doses of either ACh, an endothelium-dependent vasodilator, or nitroprusside, an
endothelium-independent vasodilator. Relaxation to both agonists was similar in aorta from L/
+ and +/+ mice (Figure S1, http://hyper.ahajournals.org). The contractile response to PGF2α,
5-HT, and ET-1 was increased in aorta from L/+ mice versus controls (Figure S2,
http://hyper.ahajournals.org). The response to the first two agonists in L/+ mice was greater in
males than females, whereas ET-1 mediated contraction in L/+ mice was observed primarily
in females (Figure S3, http://hyper.ahajournals.org). There was no difference in the contractile
response to KCl (Figure S2, http://hyper.ahajournals.org) indicating the increase in aortic
contraction was selective.
To examine the role of PPARγ in resistance vessels supplying a vital organ, we tested responses
in a cerebral artery and in cerebral arterioles. Unlike the aorta, dilation of the basilar artery in
response to the endothelial-dependent agonists ACh and A23187 was markedly impaired in L/
+ mice (Figure 1A and B). Maximal vasodilation to papaverine was similar in the L/+ and +/
+ mice (Figure 1C), indicating that the reduced responses to ACh and A23187 were selective.
There was no difference in the contraction caused by KCl (Figure 1D) or U46619 (data not
shown).
Dilation of the cerebral arterioles (∼30 μm in diameter) to ACh was markedly reduced in L/+
mice compared to controls (Figure 2A). On the contrary, the vasodilator response to
submaximal concentrations of nitroprusside and papaverine were similar in both groups of
mice (Figure 2B and C). We measured superoxide levels using dihydroethidine (DHE) staining
and observed a nearly a 2-fold increase in fluorescence in arterioles from L/+ mice (Figure 3).
Consistent with increased oxidative stress, the impairment of ACh-mediated vasodilation from
L/+ mice was reversed by Tempol, a scavenger of superoxide (Figure 4). Tempol alone had
no effect on baseline diameter of cerebral arterioles (31±1 vs 32±1 μm).
Before deactivation with EDTA, diameter of cerebral arterioles was not different in L/+ mice
from that in control mice (Table S3, http://hyper.ahajournals.org). During maximal dilation
with EDTA, external and internal diameter was less in cerebral arterioles in L/+ mice at all
levels of arteriolar pressure (Figure 5A and D). Wall thickness and cross-sectional area of the
vessel wall was greater in L/+ mice compared to controls (Figure 5B and C). The stress-strain
curve in cerebral arterioles in L/+ mice was shifted to the right of the curve in wild-type mice
(Figure S4, http://hyper.ahajournals.org). Thus, cerebral arterioles in L/+ mice underwent
hypertrophy with an increase in distensibility and a reduction in external diameter. The changes
we observed occurred in mice exhibiting only a small average (7 mmHg) increase in systolic
blood pressure, consistent with previous work 12. When separated by gender, male mice
exhibited a 10 mmHg increase in blood pressure whereas blood pressure in female mice was
unchanged (Table S3, http://hyper.ahajournals.org). Despite the difference in blood pressure
by gender, there was an equivalent reduction in external diameter and increase in cross-
sectional area in both males and females. Therefore it is unlikely that the structural changes
observed are due to the small increase in systemic arterial pressure.
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We addressed the hypothesis that PPARγ maintains normal vascular structure and function.
We reasoned that if PPARγ directly plays a protective role in the vasculature, a dominant
negative mutation causing impaired PPARγ activity should result in impaired vascular function
and altered vascular growth. Moreover, it allowed us to examine the importance of PPARγ
using a genetic approach without the need for synthetic agonists which may have non-specific
PPARγ-independent effects [reviewed in 11].
There are a number of key findings from our work. First, there was no evidence for impaired
endothelial function in the aorta as measured by the response to ACh. However, an increase
in vasoconstrictor responses was observed to several receptor-mediated agonists but not to
KCl. Second, we showed that interference with PPARγ signaling decreased responses to
endothelial-dependent vasodilators in the cerebral vasculature both in vitro and in vivo. That
the response to the endothelial-independent agonists were normal suggests the dysfunction lies
primarily in the endothelium and not smooth muscle. Third, the mechanism causing endothelial
dysfunction in cerebral arterioles in response to interference with PPARγ activity involved
oxidative stress since superoxide was increased and Tempol restored responses to ACh. Fourth,
interference with PPARγ activity resulted in hypertrophy (an increase in vessel cross sectional
area) and inward remodeling in cerebral arterioles. Collectively, these data suggest that
PPARγ plays a pivotal role in regulating vascular structure and function. The impact of
PPARγ was prominent in the cerebral circulation but the data also imply that PPARγ may play
a greater role in resistance vessels than in larger conduit vessels.
We previously reported that rosiglitazone, a high affinity synthetic PPARγ agonist improved
endothelial function in a model of non-diabetic hypertension 5. Consequently, we were
surprised that the dominant negative mutation in PPARγ did not cause obvious impairment of
endothelial function in the aorta although contractility was modestly augmented for selected
agonists. Interestingly, heterozygous endothelial NO synthase (eNOS) deficient mice respond
normally to ACh but their vasoconstrictor response to 5-HT is augmented 18. The increased
contraction to 5-HT, and perhaps PGF2α, is particularly interesting because vasoconstriction
to 5-HT is normally inhibited by eNOS 19. Thus under baseline conditions in P465L mice,
increased contractility to 5-HT, PGF2α and ET-1 may be due to a decrease in basal NO.
Unlike the aorta, we observed marked impairment in endothelial function in the cerebral
circulation. Several possibilities may explain this striking difference in vascular phenotype.
First, it is possible that the impact of PPARγ on endothelial function is greater in resistance
vessels than in larger vessels such as aorta. Second, there may be regional differences in the
functional importance of PPARγ. For example, endothelium of the brain constitutes the blood-
brain barrier which has unique biochemical and metabolic characteristics. Third, levels of
expression of PPARγ may be higher in cerebral blood vessels than in conduit vessels or in
other vascular beds such that interference with normal PPARγ activity has a greater functional
impact in cerebral circulation. Fourth, differences in pro- and anti-oxidant mechanisms in the
vessel wall and the impact of PPARγ on these mechanisms may differ in cerebral blood vessels.
Our observations of increased superoxide in cerebral arterioles and that Tempol restores
responses to ACh suggests that inhibition of oxidative stress is one of the key mechanisms by
which PPARγ exerts protective effects on endothelial function. One source of oxygen-derived
free radicals in the vasculature is NAD(P)H oxidase. PPARγ inhibits NAD(P)H oxidase
activity but also induces expression of CuZn-SOD, critical in the scavenging of superoxide
10, 20. These results suggest that PPARγ expression in the vascular wall may play a physiologic
role as a regulator of genes involved in oxidative stress, even though the details of these actions
remain to be completely defined.
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Our data are very consistent with vascular protective effects predicted for PPARγ based on the
protective effects of PPARγ agonists in humans and animal models. However, the strength of
our data lies in making a genetic connection between PPARγ and vascular structure and
function independent of off-target effects of PPARγ agonists. Indeed, non-specific effects of
PPARγ agonists have been reported [reviewed in 11].
One of the most interesting phenotypes we observed in P465L mice relates to altered structure
of the vasculature. There are multiple determinants of vascular hypertrophy including blood
pressure, the renin-angiotensin system, and reactive oxygen species. Tsai et al. previously
reported that L/+ mice exhibit an small increase in blood pressure 12, a finding replicated in
the male L/+ mice examined herein. That cerebral arteriolar pressure does not differ between
L/+ and +/+ mice, and the systemic arterial pressure of female L/+ mice was not different from
control mice despite a similar change in hypertrophy and remodeling, strongly suggests that
these structural and functional changes occur independent of blood pressure.
Hypertrophy of cerebral arterioles has been observed previously in several models including
mice with angiotensin-II-dependent hypertension 21, 22. In the present study, we found that
cerebral arterioles in P465L mice had increased cross-sectional area compared to controls.
These findings are consistent with previous studies in vascular muscle in culture which
suggested that pharmacological activation of PPARγ reduces vascular hypertrophy, possibly
through effects on the renin-angiotensin system 23. In vivo, synthetic activators of PPARγ
protect against abnormal vascular growth during angiotensin II-dependent hypertension 24. In
contrast to hypertrophy, much less is known regarding determinants of vascular remodeling.
We define inward vascular remodeling as a reduction in vessel diameter that cannot be
attributed to altered distensibility of the vessel wall. Although vascular hypertrophy is present
in diverse models 16, 21, 22, inward vascular remodeling was only observed in mice with
angiotensin II-dependent hypertension 22. Based on these findings, we have proposed that the
renin-angiotensin system may be a key determinant of vascular remodeling 22. Similar to what
is observed with angiotensin II-dependent hypertension, hypertrophy and inward vascular
remodeling were seen in mice expressing a dominant negative form of PPARγ. In this regard,
it is noteworthy that angiotensin II produces such vascular changes and the renin-angiotensin
system is a target of PPARγ.
Perspectives
Our data provide compelling genetic evidence that PPARγ plays an important role in protecting
the vasculature. Interference with PPARγ results in hypertrophy and inward remodeling of
resistance vessels and impairment of endothelial function in the cerebral circulation. The model
employed herein is one of global interference with PPARγ function. Parallel efforts are
beginning to define the role of PPARγ in specific cell types. For example, endothelial-specific
knockout of PPARγ using cre-loxP caused an increase in arterial pressure after feeding a high
fat diet 25. Similarly, strong interference with PPARγ function specifically in vascular muscle
caused vascular dysfunction and hypertension 26.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Impaired Endothelial Function in Basilar Artery from P465L Knockin Mice
Dilation of the basilar artery from L/+ and +/+ mice in response to ACh (A), A23187 (B), or
100 mmol/L papaverine (C). The constrictor response to KCl (50 mmole/L) was measured (D).
*, P<0.01. The P value comparing the dose response curves is indicated.
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Figure 2. Impaired Endothelial Function in the Cerebral Circulation In Vivo
Dilation of cerebral arterioles from L/+ and +/+ mice measured in response to ACh
(A),nitroprusside (B), or papaverine (C). *, P<0.05.
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Figure 3. Increased Superoxide in Cerebral Arterioles
Representative confocal fluorescent sections and relative fluorescence in cerebral arterioles of
wild-type mice (+/+, left) and P465L mice (L/+, center) incubated with hydroethidine (2 μmol/
L for 30 minutes) for detection of O2−. Values are means ±SEM in 37 vessels from 10 +/+
mice and 39 vessels from 10 L/+ mice. *P<0.05 vs wild-type mice. Scale bar = 20 μm.
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Figure 4. Tempol Reverses Endothelial Dysfunction in the Cerebral Circulation In Vivo
Dilation of cerebral arterioles from untreated +/+, untreated L/+ and Tempol-treated L/+ mice
measured in response to ACh. *, P<0.05.
Beyer et al. Page 12













Figure 5. Structural and Mechanical Changes in Cerebral Arterioles in P465L mice
External and internal diameter of cerebral arterioles after maximal dilation (A), wall thickness
(B) cross-sectional area (CSA) of the vessel wall in arterioles (C), pressure-internal diameter
relationships in arterioles during maximal dilation (D), in wild-type (+/+) and L/+ mice.
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